BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Press Releases

  Novavax’s Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

  August 28, 2026

   · 

  6 min read
• Press Releases

  Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA’s Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

  August 28, 2026

   · 

  5 min read
• Press Releases

  Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer

  August 28, 2026

   · 

  2 min read
• 

  Bankruptcy

  BioXcel files for bankruptcy, plans to sell assets to Teva for up to $125M

  Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.

  August 28, 2026

   · 

  2 min read

   · 

  Michael Gibney
• 

  cardiovascular disease

  ‘Worse than expected’ Wainua data muddies water for TTR silencers

  AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say.

  August 28, 2026

   · 

  2 min read

   · 

  Gabrielle Masson
• 

  Cancer

  BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer

  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.

  August 28, 2026

   · 

  2 min read

   · 

  Heather McKenzie
• Press Releases

  ACG appoints Rajesh Bhogavalli as Group Chief Commercial Officer

  New Group Chief Commercial Officer to support next phase of international growth

  August 28, 2026

   · 

  1 min read
• Press Releases

  Theralase(R) Releases Q2 2026 Financial Statements

  Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

  August 28, 2026

   · 

  11 min read
• Press Releases

  Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update

  August 28, 2026

   · 

  3 min read